SCHEMBL7666306

SCHEMBL7666306

CC(=O)On1c(=O)c(-c2cn(Cc3cccc(CN)c3)c3ccccc23)nc2cc3nccnc3cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 4/20 0.39
CYP1A2 P05177 4/20 0.39
CYP3A4 P08684 4/20 0.39
CASP1 P29466 3/20 0.39
CASP7 P55210 3/20 0.39
CYP2C9 P11712 3/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
PDE4A P27815 8/20 0.38
PDE4B Q07343 8/20 0.38
PDE4C Q08493 8/20 0.38
PDE4D Q08499 8/20 0.38
PDE3B Q13370 4/20 0.37
PDE3A Q14432 4/20 0.37
POLB P06746 1/20 0.37
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CHRM1 P11229 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7659856 0.95 PDE4A (0.38) USP2CYP1A2CYP3A4CASP1CASP7
SCHEMBL7662061 0.92 POLB (0.38) USP2CYP1A2CYP3A4CASP1CASP7
SCHEMBL7657926 0.91 USP2 (0.41) USP2CYP1A2CYP3A4CASP1CASP7
SCHEMBL7660922 0.87 PDE4A (0.37) USP2CYP1A2CYP3A4CASP1CASP7
SCHEMBL7652540 0.87 PDE4A (0.37) USP2CYP1A2CYP3A4CASP1CASP7
SCHEMBL7851651 0.87 PDE4A (0.38) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL8516249 0.86 F2RL3 (0.40) USP2CYP1A2CYP3A4CASP1CASP7
SCHEMBL7654522 0.86 ALDH1A1 (0.42) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL7662107 0.84 CAMK2D (0.45) USP2CYP1A2CYP3A4CYP2C9ALDH1A1
SCHEMBL7664699 0.83 POLB (0.36) USP2CYP1A2CYP3A4CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed
EP-1071683-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2001-01-31 EP disclosed
WO-1999046264-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-09-16 WO disclosed